New Anti-Endoparasitic Composition Patents

7 January 2013

TyraTech, Inc.

(the "Company" or "TyraTech")

New Anti-Endoparasitic Composition Patents for Human and Animal Health

Patents Protect New Human and Animal Health Anthelmintic Pipeline Products

TyraTech, Inc. (AIM: TYR and TYRU), a natural life sciences company, is pleased to announce that the Company has received notices, from both the United States Patent and Trademark Office and the State Intellectual Property Office of the People's Republic of China, granting two new patents for the Company's novel natural compositions for controlling intestinal worms and parasites.

The World Health Organization estimates that over 2 billion people suffer from intestinal parasite infections with more than half of these incidences being found in children between the ages of 7 and 14 years. The infections can result in debilitating conditions such as malnutrition, anemia, immune suppression and delayed intellectual development in children.

In animals, intestinal parasites have a significant impact on both productivity and wellbeing. In addition, companion animals in particular, have the potential to transmit parasites on to humans.

The Directors of the Company believe that these new patents are an important addition to TyraTech's intellectual property portfolio as they will provide support and protection of the Company's pipeline of anthelmintic solutions for humans, as well as companion and production animals.

The issuance of these patents increases TyraTech's patent portfolio to a current total of fourteen United States and international patents protecting its proprietary screening platform and compositions.

Alan Reade, Executive Chairman of the Company said:

"These new patents further confirm TyraTech as an innovative human and animal health company. We believe that these additional patents will help the Company create an array of exciting opportunities in the human and animal health markets.

"Additionally, the expansion of our IP portfolio validates our position at the forefront of developing best-in-class solutions capable of delivering the highest levels of efficacy and safety for people, pets, and production animals. Intestinal parasite infections have a very negative impact on millions of young people in many areas of the world. TyraTech is therefore particularly satisfied to have the opportunity to commercialise a very safe and effective solution to a significant public health issue."

For further information please contact:

TyraTech Inc.Alan Reade, Executive ChairmanTel: +1 919 415 4310

Peter Jerome, Chief Financial OfficerTel: +1 919 415 4280

N+1 Singer, Nominated Adviser and Joint BrokerAubrey Powell / Alex WrightTel: +44 20 7496 3000

First Columbus LLP, Joint BrokerChris CrawfordTel: +44 20 3002 2070